Clinical Trial Update: Prazosin Treatment for Disruptive Agitation in Alzheimer's Disease [NA]

View source ↗

Summary

Clinical trial update indicating the completion of NCT01126099 evaluating prazosin for disruptive agitation in Alzheimer's disease. Results were posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Prazosin (prazosin)

Snippet

Sponsor: Seattle Institute for Biomedical and Clinical Research | Conditions: Alzheimer's Disease | NA | Status: COMPLETED | Results posted: 2015-05-21